Armstrong Henry H Associates Inc. Lowers Holdings in Novo Nordisk A/S $NVO

Armstrong Henry H Associates Inc. lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 6.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,433 shares of the company’s stock after selling 591 shares during the quarter. Armstrong Henry H Associates Inc.’s holdings in Novo Nordisk A/S were worth $582,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVO. Copeland Capital Management LLC boosted its holdings in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after acquiring an additional 255 shares during the period. North Capital Inc. purchased a new position in Novo Nordisk A/S in the 1st quarter worth approximately $27,000. Park Square Financial Group LLC purchased a new position in Novo Nordisk A/S in the 4th quarter worth approximately $29,000. Stone House Investment Management LLC purchased a new position in Novo Nordisk A/S in the 1st quarter worth approximately $30,000. Finally, Disciplina Capital Management LLC boosted its holdings in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 297 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NVO. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 31st. TD Cowen cut their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 19th. Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. UBS Group lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. Finally, HSBC lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $57.00 price target on the stock. in a research report on Thursday, July 31st. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $81.00.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $54.94 on Friday. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $138.22. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The business’s fifty day moving average price is $57.96 and its two-hundred day moving average price is $66.33. The firm has a market capitalization of $245.31 billion, a PE ratio of 15.09, a P/E/G ratio of 2.06 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.